Results Nearly half the patients were initially admitted for another reason, mainly pain. When the acute chest syndrome was diagnosed, patients had hypoxia, decreasing hemoglobin values, and progressive multilobar pneumonia. The mean length of hospitalization was 10.5 days. Thirteen percent of patients required mechanical ventilation, and 3 percent died. Patients who were 20 or more years of age had a more severe course than those who were younger. Neurologic events occurred in 11 percent of patients, among whom 46 percent had respiratory failure. Treatment with phenotypically matched transfusions improved oxygenation, with a 1 percent rate of alloimmunization. One fifth of the patients who were treated with bronchodilators had clinical improvement. Eighty-one percent of patients who required mechanical ventilation recovered. A specific cause of the acute chest syndrome was identified in 38 percent of all episodes and 70 percent of episodes with complete data. Among the specific causes were pulmonary fat embolism and 27 different infectious pathogens. Eighteen patients died, and the most common causes of death were pulmonary emboli and infectious bronchopneumonia. Infection was a contributing factor in 56 percent of the deaths.
Conclusions
Among patients with sickle cell disease, the acute chest syndrome is commonly precipitated by fat embolism and infection, especially community-acquired pneumonia. Among older patients and those with neurologic symptoms, the syndrome often progresses to respiratory failure. HE acute chest syndrome is the leading cause of death and hospitalization among patients with sickle cell disease. [1] [2] [3] The optimal treatment has not been established because the cause remains largely unknown. Both infectious and noninfectious causes have been described, but their frequency and clinical course are unknown. [4] [5] [6] [7] [8] [9] [10] [11] [12] Pulmonary fat embolism has been identified during autopsies and in studies examining fatladen pulmonary macrophages from bronchoalveolar fluid. 4, [11] [12] [13] However, the number of patients included in these reports is too small for general recommendations to be made. 11 Appropriate therapy remains controversial. The antibiotics used are based on organisms identified decades ago, and data regarding the use of new antibiotics for emerging pathogens are limited. Antiviral treatments have not been carefully studied in patients with sickle cell disease. Furthermore, the benefit of transfusion and bronchodilator therapy has not been clearly established.
In 1993, we initiated a prospective, multicenter study of the acute chest syndrome in order to determine the causes, incidence, and clinical outcome of the syndrome and factors that predict prognosis.
stitutional review board at each participating center approved the study. To be eligible, patients had to have a phenotype of hemoglobin SS, hemoglobin SC, or hemoglobin SS-b -thalassemia on electrophoretic analysis of the hemoglobin chains and to have had an episode of the acute chest syndrome. The acute chest syndrome was defined on the basis of the finding of a new pulmonary infiltrate involving at least one complete lung segment that was consistent with the presence of alveolar consolidation, but excluding atelectasis. In addition, the patients had to have chest pain, a temperature of more than 38.5°C, tachypnea, wheezing, or cough.
From March 1993 through March 1997, 721 episodes of the acute chest syndrome were reported. Fifty episodes were excluded: 30 because of missing forms, and 20 because of diagnostic error and withdrawal from the study. Data were available on 671 episodes in 538 patients, including 443 patients with a single episode and 95 with recurrent episodes (69 with two episodes, 16 with three episodes, 8 with four episodes, and 2 with five episodes).
Treatment Protocol and Data Collection
A standardized treatment and monitoring protocol was used (Fig. 1) . Transfusion guidelines included the use of units that were depleted of leukocytes, negative for sickle cells, and matched with respect to Rh C and E antigens and Kell antigens. Patients were monitored for alloantibodies by standard tests at enrollment, before and after each transfusion, and at follow-up. Patients received transfusions to improve respiratory status at the discretion of their physicians. Standardized forms were used to document medical history, findings on daily physical examinations, findings on radiography, oxygenation status, the need for transfusions, complications of bronchoscopy, and findings on follow-up.
Laboratory Studies and Diagnostic Criteria
Blood for culture was obtained before therapy whenever possible. Bronchoscopy was performed to obtain samples for aerobic and anaerobic cultures and for the fat embolism assay. In patients who did not undergo bronchoscopy, sputum was collected either after the inhalation of aerosolized saline or by tracheal aspiration. 11 A bacterial cause of the acute chest syndrome was identified on the basis of a positive blood culture or heavy growth of an organism in a bronchial culture with confirmatory results on Gram's staining.
Bronchial and nasopharyngeal samples were used for standard viral cultures, 14 and cultures for mycoplasma were performed with use of SP4 and A8 mediums. 15 All viral and mycoplasma isolates were identified by immunofluorescence staining with specific reagents. Legionella pneumophila serogroups 1 through 6 were detected by indirect immunofluorescence staining.
Serum samples were collected during the acute phase of illness and during convalescence; the median interval between sample collection was 48 days. An increase in antibody titers by a factor of at least 4 during this interval was used to diagnose Mycoplasma pneumoniae, 16 parvovirus B19, 17 and Epstein-Barr virus. 18 Increases were confirmed by specific IgM antibody tests.
In a subgroup of patients, pairs of serologic samples and bronchoscopic or sputum samples were sent to the laboratory of Dr. Julias Schachter (University of California, San Francisco) for culture for chlamydia and for measurement of chlamydia antibody titers according to the microimmunofluorescence technique. 19 Nasopharyngeal samples were further analyzed by the polymerase chain reaction. 20 The diagnosis of Chlamydia pneumoniae infection was based on an increase in IgG antibody titers by a factor of 4 in the absence of cross-reactivity with C. trachomatis on microimmunofluorescence analysis, an initial IgM antibody titer of more than 1:16, or a positive polymerase-chain-reaction assay.
Intracellular lipid from alveolar macrophages obtained from bronchial samples was evaluated for evidence of pulmonary fat embolism according to a modification of the Corwin index, a method for quantification of the amount of lipid found in pulmonary macrophages. 11 Samples obtained at autopsy and histopathological slides were analyzed by the central pathology unit for evidence of sickle cell disease.
Statistical Analysis
We performed inferential statistical analyses after eliminating all but the first episode of the acute chest syndrome for each patient. For comparisons of clinical data among age groups, we compared proportions using chi-square analysis with Yates' correction or Fisher's exact test. All confidence intervals were two-sided, and a P value of 0.05 or less was considered to indicate statistical significance. For comparison of means, we used Student's t-test or analysis of variance; results are reported as means ±SD. When assumptions for parametric analyses were not met, the Wilcoxon rank-sum test was used. When summarizing data concerning causation, we included all episodes.
We developed a Cox proportional-hazards regression model for the duration of hospitalization in which we reduced age and 40 other variables from the patients' medical history and hospital course to 19 covariates that were significant on univariate analyses. These variables were included in a multivariable proportional-hazards regression model designed to identify factors that were independently associated with the time of discharge from the hospital. Data on patients were censored at the time of death, and one variable for which more than 20 percent of values were missing was not entered into the model.
Multivariable logistic-regression models were developed for the presence or absence of respiratory failure and neurologic complications in order to identify predictors of these events at the time of diagnosis. We performed univariate logistic-regression analyses of these outcomes and 35 clinical variables of interest. Only clinical variables that were significantly related in the univariate analyses to the outcome variable were included in the multivariable logisticregression model.
RESULTS

Diagnosis and Symptoms of the Acute Chest Syndrome at Admission
The characteristics of the patients are summarized in Table 1 . Data on one patient (one episode) were excluded because the patient's birth date was not known. Nearly half the patients were admitted with a diagnosis other than the acute chest syndrome; 72 percent of these patients were admitted because of a vaso-occlusive crisis. Among patients who were not admitted for the acute chest syndrome, radiographic and clinical findings of the syndrome appeared a mean of 2.5 days after admission. The symptoms at presentation varied with age (Table 1) .
Hospital Course and Treatment
The findings on physical and radiographic examination are summarized in Table 2 . During hospitalization, multilobar involvement, especially of the lower lobes, was common in all age groups, and effusion was present in 55 percent of all patients. All patients were treated with antibiotics and, on average, became afebrile after a mean of two days of hospitalization.
At diagnosis, the mean oxygen saturation was 92 percent while the patients were breathing room air. There was no significant difference in the extent of hypoxia among the age groups, but younger patients were less likely to be treated with oxygen and mechanical ventilation. Thirteen percent of all patients required mechanical ventilation, and the mean duration of mechanical ventilation was 4.6 days. Eightyone percent of the patients who required mechanical ventilation recovered. 
Treatment
Oxygen therapy required for patients with a partial pressure of arterial oxygen of less than 60 mm Hg or oxygen saturation of less than 90 percent.
Antibiotic therapy, consisting of cephalosporin and erythromycin intravenously until fever had been absent for at least 24 hours and then orally, for a total of 7 to 10 days, given to all patients.
Fluid management individualized on the basis of cardiopulmonary status. 1 to 1 1 ⁄2 times daily fluid requirements (intravenous plus oral), with modifications based on daily weight and intake and output analysis.
Respiratory therapy consisting of incentive-spirometry protocol for all patients who were able to perform it.
Pain-management protocol included guidelines for patient-controlled analgesia and dosages of narcotics and nonsteroidal agents, with the goal being to prevent respiratory splinting and avoid hypoventilation and narcosis; cardiorespiratory monitoring was continuous.
Bronchodilator therapy given to patients with evidence of reactive airway disease. Transfusion therapy given to patients for clinical distress, at physician's discretion.
Laboratory Monitoring
Daily blood count, serial chemistry panels.
Pretransfusion and post-transfusion studies, including concentrations of hemoglobin S and partial pressure of oxygen.
Continuous (or every 8 hours) pulse oximetry.
Daily arterial-blood gas measurements until partial pressure of arterial oxygen was 75 mm Hg or greater while patient was breathing room air.
Daily chest radiography until improvement was documented.
Pulmonary-function tests at onset of episode, at discharge, and at the 6-week follow-up visit in patients who were able to participate.
Enrollment of 538 patients with 671 episodes of acute chest syndrome
Diagnostic Tests
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The mean forced expiratory volume in one second during the acute phase of the syndrome was 53 percent of the predicted value. Sixty-one percent of patients were treated with bronchodilators, and 20 percent of these patients had clinical improvement (defined as an increase of 15 percent in forced expiratory volume in one second, expressed as a percentage of the predicted value). Among those with improvement, the mean forced expiratory volume in one second was initially 41 percent of the predicted value and increased to 52 percent, a 27 percent improvement.
Seventy-two percent of patients received transfusions ( Table 2 ). The mean number of transfusions per patient was 1.6, and the mean number of units per patient was 3.2. Sixty-eight percent of patients *Because of rounding, percentages may not total 100. Data on one patient were excluded because the patient's birth date was not known. †P values were calculated by chi-square analyses. ‡Other reasons included a vaso-occlusive event, anemia, fever, infection, gastrointestinal or abdominal pain, asthma, urologic and orthopedic conditions, heart failure, and surgery. *Data on one patient were excluded because the patient's birth date was not known. †P values were calculated by chi-square analyses. ‡The partial pressure of arterial oxygen was measured while the patient was breathing room air. §Oxygen saturation was measured by pulse oximetry while the patient was breathing room air. ¶This category included any painful episode that occurred during hospitalization.
¿This category included respiratory failure, pneumothorax, and empyema requiring thoracentesis.
**This category included arrhythmia, congestive heart failure, hypertension, and hypotension. † †This category included gastrointestinal hemorrhage, ileus, and bowel infarction. ‡ ‡This category included all days of hospitalization, even those that occurred before the diagnosis of the acute chest syndrome in the case of patients who were admitted for reasons other than the syndrome. The mean hospital stay was 10.5 days. Cox proportional-hazards regression analysis of 19 covariates that were significant on univariate analysis showed that after adjustment for the remaining factors, an age of 20 years or more, a history of vaso-occlusive events, a platelet count of 0 to 199,000 per cubic millimeter at diagnosis, pain in the arms and legs at presentation, extensive radiographic abnormalities, evidence of effusion on radiographic analysis, fever, treatment by transfusion, and respiratory failure were independently associated with prolonged hospitalization (Table 3) .
T ABLE 2. C HARACTERISTICS AND T REATMENT OF
Complications
Older patients (particularly those who were 20 years of age or older) were more likely to have complications and to die during hospitalization (Table 2) . Respiratory failure was documented in 13 percent of patients. To identify predictors of respiratory failure that were present at the time of diagnosis, we developed a multivariable logistic-regression model that included age and 10 variables that were significant on univariate analyses. Radiographic evidence of extensive lobar involvement, a platelet count of 0 to 199,000 per cubic millimeter at diagnosis, and a history of cardiac disease remained independent predictors of respiratory failure (Table 3) .
Neurologic events occurred in 11 percent of patients. The most common were altered mental status (in 56 percent), seizures (11 percent), and neuromuscular abnormalities (8 percent) . Anoxic brain injury occurred in three patients, central nervous system hemorrhage in three, and infarction in three. Respiratory failure developed in 46 percent of patients with neurologic complications; 92 percent of these patients underwent transfusion, and 23 percent died. The mean hospital stay for these patients was 19.5 days, as compared with 9.4 days for the remainder of the patients (P=0.008). Multivariable logistic-regression analysis of 11 variables that were significant on univariate analysis showed that only the platelet count remained an independent predictor of neurologic complications during hospitalization (Table 3) . Those with relative thrombocytopenia (defined as a platelet count of less than 200,000 per cubic millimeter) were at the greatest risk for neurologic complications.
Complications occurred in 13 percent of all bronchoscopic procedures (28 of 219). Half the complications consisted of a transient decline in oxygen saturation. Laryngospasm occurred in 10 patients, and pneumothorax developed in 2 patients, both of whom had had the acute respiratory distress syndrome before the bronchoscopy. Eight patients underwent intubation because of bronchoscopic complications. As compared with the patients who underwent bronchoscopy without incident, the patients who had complications were more likely to present with dyspnea (61 percent vs. 36 percent, P=0.04) and higher peak respiratory rates (mean, 47 vs. 41 per minute; P=0.03).
Eighteen patients died. The primary causes of death were respiratory failure from pulmonary emboli (bone marrow, fat, or thrombotic) in six patients and bronchopneumonia in six. The causes of death in the remaining patients were pulmonary hemorrhage, cor pulmonale, hypovolemic shock from splenic sequestration, overwhelming sepsis, intracranial hemorrhage, and seizure. Overall, infection was a contributing factor in 10 deaths. The organisms identified included Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, legionella, cytomegalovirus, Staphylococcus aureus, and chlamydia.
Causes of the Acute Chest Syndrome
The causes of the acute chest syndrome are given in Table 4 . A specific cause (either pulmonary fat embolism or an infectious agent) was identified in 256 (38 percent) episodes. After the exclusion of episodes with incomplete data, a specific cause was identified in 70 percent of episodes. Pulmonary infarction was presumed to be the cause in 16 percent of episodes in which there were complete data but no cause could be identified.
Bronchoscopic or sputum samples were obtained for analysis of fat embolisms in 72 percent of episodes. The results for 15 percent of the bronchoscopic specimens could not be interpreted. The majority of these specimens contained large quantities of inflammatory cells that made it impossible to identify pulmonary macrophages. A significantly larger percentage of sputum samples were uninterpretable (42 percent, P<0.001), in most cases because of contamination with epithelial cells from the oropharynx or an inflammatory exudate.
Of the 27 different pathogens identified, C. pneumoniae was the most frequent, followed by M. pneumoniae and respiratory syncytial virus (Table 5 ). Parvovirus was isolated from a bronchial sample in 10 *Only risk factors that were significant on multivariable regression analysis are included. CI denotes confidence interval. †Cox regression analysis was used, with data on patients who died censored at the time of death. ‡Respiratory failure was defined as the need for mechanical ventilation. §Odds ratios are given for risk factors that were significant on multivariable logistic regression. Only risk factors that were present at the time of diagnosis were included in the models. episodes. Severe reticulocytopenia was present in 5 of these 10 episodes. In total, 249 pathogens were identified in 216 episodes. A single infectious pathogen was identified in 172 episodes, multiple pathogens were identified in 25 episodes, and fat embolism was diagnosed together with an infectious agent in 19 episodes.
Comparison of Pulmonary Fat Embolism, Infection, and Infarction
We compared the characteristics of 53 patients with fat embolism as a cause of a first episode of the acute chest syndrome, 157 with infection as a cause, and 82 with infarction as the presumed cause. More patients in the fat-embolism group than in the infection group or the infarction group were 20 years of age or older (30 percent vs. 22 percent and 13 percent, P=0.003). The patients in the fat-embolism group also had a lower mean oxygen saturation at presentation (89 percent vs. 94 percent and 91 percent, P=0.02) and were more likely to have upperlobe infiltrates during hospitalization (45 percent vs. 38 percent and 24 percent, P=0.04). The overall rates of complications were similar in the three groups, except for a higher incidence of vaso-occlusive events in the fat-embolism group (74 percent vs. 54 percent and 68 percent, P=0.02).
Comparison of Chlamydia and Mycoplasma Infections
We also compared the characteristics of the patients who were infected with the two most common pathogens. As compared with patients with mycoplasma infections, patients with chlamydia infections were older (mean age, 17.8 vs. 11.3 years; P=0.02), were less likely to be taking prophylactic antibiotics (43 percent vs. 77 percent, P=0.006), and were more likely to have a vaso-occlusive event during hospitalization (65 percent vs. 39 percent, P=0.04). At diagnosis, patients with chlamydia infections had higher mean hemoglobin levels than did patients with mycoplasma infections (8.0 vs. 7.0 g per deciliter, P=0.03).
In seven episodes M. hominis was the only agent identified. The patients with M. hominis infections were older than those with M. pneumoniae infections (mean age, 19.6 vs. 10.2 years) but were similar in other respects.
DISCUSSION
Although there is an increased awareness that the acute chest syndrome is the leading cause of death *Data on one episode were excluded because the patient's birth date was not known. †Nineteen of the episodes of pulmonary fat embolism were associated with infectious pathogens. ‡This category included episodes in which chlamydia alone was identified but not episodes involving mixed infections or pulmonary fat embolism. §This category included episodes in which only Mycoplasma pneumoniae or Mycoplasma hominis was identified, but not episodes involving mixed infections, Mycobacterium tuberculosis, or pulmonary fat embolism. ¶This category included two cases of tuberculosis and one case of Mycobacterium avium complex infection.
¿A pulmonary infarction was presumed to have occurred during episodes in which the results of the analysis for pulmonary fat embolism, bacterial studies, viral-isolation studies, and serologic tests were complete and were all negative. **The cause of episodes for which some or all of the diagnostic data were incomplete and no etiologic agent was identified was considered to be unknown. in patients with sickle cell disease, the diagnosis is often delayed, the optimal treatment is unknown, and the cause is usually not determined. The longer patients with sickle cell disease live, the higher the frequency of recurrent pulmonary disease and resultant chronic lung disease. 21 Despite the young age of our patients, more than two thirds had a history of the acute chest syndrome, and many had multiple episodes during the study. The symptoms at presentation were age-dependent; wheezing, cough, and fever were most common among patients who were younger than 10 years of age, whereas pain in the arms and legs and dyspnea were more common among the adults. 22 Almost half the patients in whom the acute chest syndrome developed were admitted for other reasons, including pain, and had radiographic and clinical symptoms within three days after hospitalization. Clearly, pain is a prodrome of the acute chest syndrome, 22, 23 and a single physical examination or radiograph may not be adequate for early diagnosis.
Laboratory values worsened after the diagnosis of the syndrome despite aggressive intervention. As in previous studies, we found that involvement of the lower lobes predominated, 9,22 radiographic abnormalities progressed, and oxygenation and hemoglobin levels declined. These findings indicate that serial monitoring is necessary.
The average length of hospitalization was more than 10 days and was longer than that reported in previous studies. 8, 9 An older age, pain in the arms and legs at presentation, fever, a low platelet count at diagnosis, extensive radiographic abnormalities, transfusion therapy, and respiratory failure were associated with prolonged hospitalization. At the time of diagnosis of the acute chest syndrome, patients who went on to have respiratory failure were more likely to have a history of cardiac disease, to have four or more lobes affected, and to have platelet counts of 0 to 199,000 per cubic millimeter at base line. In the general population, similar findings have been found to be predictive of the severity of pneumonia, the acute respiratory distress syndrome, and the acute multiorgan-failure syndrome. [24] [25] [26] There is a strong relation between the acute chest syndrome and the occurrence of neurologic complications. Neurologic complications developed in 22 percent of the adults in our study. In nearly half these patients, respiratory failure subsequently developed. A recent history of a pulmonary event is the nonneurologic risk factor that is the most highly predictive of stroke. 27 The mechanism most likely involves sudden decreases in oxygenation in the vascular bed of the central nervous system. 27, 28 Although our statistical model included only a small number of neurologic events, the occurrence of relative thrombocytopenia has been associated with neurologic ischemic insults and reflects the presence of hypoxia, tissue damage, and platelet consumption. 29, 30 In addition, fat embolism and infection with chlamydia or mycoplasma may also play a direct part in brain injury. 31, 32 Our study evaluated interventions such as transfusions, bronchodilators, antibiotics, and mechanical ventilation. Almost three quarters of the patients received transfusions because of a worsening clinical course. Both exchange and simple transfusions improved oxygenation, providing evidence to support studies that demonstrate that limited transfusions alleviate organ dysfunction. [33] [34] [35] The use of phenotypically matched units resulted in a 1 percent rate of alloimmunization, which is lower than the rate of 7 percent that is associated with standard transfusions, 33 and pulmonary function improved with bronchodilator therapy. The 81 percent rate of recovery after mechanical ventilation is better than the rate among patients with the acute respiratory distress syndrome. 36 The cause of the acute chest syndrome was established in 38 percent of episodes, and pulmonary infarc-*All infectious agents isolated during episodes of the acute chest syndrome are included. tion was the presumed cause in another 16 percent. In contrast to prior studies, in which specific causes were seldom identified, 2,22 infection and emboli were common causes in our study. We examined bronchoalveolar-lavage fluid because of previous reports of the successful identification of bacterial pathogens and pulmonary fat embolism in such specimens. [10] [11] [12] 37, 38 Bronchoscopy produced higher-quality samples than did the collection of sputum, although this procedure was associated with a risk of complications. However, in 85 percent of samples, adequate material was collected and the diagnostic yields were high. We identified a large number of organisms that have not usually been associated with the acute chest syndrome. Chlamydia was the most common isolate and was associated with an increased rate of vaso-occlusive events, although the rate of infection with this organism was similar to that in the general population. 39, 40 Mycoplasma and viral pneumonia, including that caused by parvovirus, occurred in all age groups, but predominated among young children. 6 We also found that M. hominis was responsible for seven episodes of the acute chest syndrome and legionella for four. These organisms have not been considered causes of the syndrome, but they should be.
As reported in previous studies, 11, 12 pulmonary fat embolism was common in our study and the clinical course of patients with this cause varied. Although the catalyst of the syndrome may be pulmonary fat embolism or infection, these events precipitate sickling, regional hypoxia, and further ischemic damage. [41] [42] [43] [44] An environment ideal for sickle cell-related injury is created by altering cellular adhesive molecules, damaging the vascular endothelium, and stimulating cytokines. 11, 23, 41, [43] [44] [45] In order to minimize lung injury in patients with sickle cell disease, a comprehensive plan aimed at both the catalyst and the host response is needed. Patients should receive the influenza and pneumococcal vaccines, and they should be evaluated for respiratory syncytial virus vaccine. Those admitted for painful crises should be considered to be in the prodromal phase of the acute chest syndrome; they require incentive spirometry and daily monitoring for pulmonary disease.
Once the acute chest syndrome has been diagnosed, broad-spectrum antibiotics, including a macrolide, are required. Airway hyperreactivity should be assumed to be present, even if the patient is not wheezing, and treatment with bronchodilators should be initiated. Routine, early transfusions are indicated for patients at high risk for complications, including adults and those who have a history of cardiac disease and severe pain in the arms and legs at presentation. Those who present with severe anemia, thrombocytopenia, or both and multilobar pneumonia should receive a transfusion before respiratory distress develops. In most patients with anemia, treatment with leukocyte-depleted, matched, simple transfusions is safe and effective.
Bronchoscopy is recommended in patients with no response to initial therapy because of the potential for organisms to be missed by analysis of sputum samples. Preliminary reports suggest that corticosteroids and nitric oxide are beneficial in severe cases that have not responded to other treatments. 45, 46 Given the high rate of success with mechanical ventilation in our study, aggressive ventilatory support, including extracorporeal membrane oxygenation, may be necessary. After recovery, patients must be evaluated for lung injury. Hydroxyurea, transfusion therapy, or bone marrow transplantation may be indicated in patients with recurrent events.
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